The USFDA has approved Xgeva (denosumab) to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone. Skeletal-related events include bone fractures from cancer and bone pain requiring radiation.
(source: http://www.fda.gov/)
Showing posts with label Denosumab. Show all posts
Showing posts with label Denosumab. Show all posts
Monday, November 22, 2010
Subscribe to:
Posts (Atom)